{"pmid":32294289,"title":"Venous thromboembolism in COVID-19 patients.","text":["Venous thromboembolism in COVID-19 patients.","We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days.","J Thromb Haemost","Porfidia, Angelo","Pola, Roberto","32294289"],"abstract":["We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days."],"journal":"J Thromb Haemost","authors":["Porfidia, Angelo","Pola, Roberto"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294289","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14842","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664266295791583232,"score":8.233237,"similar":[{"pmid":32302456,"title":"Potential of Heparin and Nafamostat Combination Therapy for COVID-19.","text":["Potential of Heparin and Nafamostat Combination Therapy for COVID-19.","Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1). In other words, abnormal coagulation may influence the prognosis of COVID-19. This is extremely interesting. The article did not describe to what extent heparin improves the abnormal coagulation and further studies by this group are anticipated. The authors reported in that article 1) and a previous article 2) that the abnormal coagulation seen in non-survivors of COVID-19 clearly differs from the abnormal coagulation typically seen in other severe infectious diseases.","J Thromb Haemost","Asakura, Hidesaku","Ogawa, Haruhiko","32302456"],"abstract":["Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1). In other words, abnormal coagulation may influence the prognosis of COVID-19. This is extremely interesting. The article did not describe to what extent heparin improves the abnormal coagulation and further studies by this group are anticipated. The authors reported in that article 1) and a previous article 2) that the abnormal coagulation seen in non-survivors of COVID-19 clearly differs from the abnormal coagulation typically seen in other severe infectious diseases."],"journal":"J Thromb Haemost","authors":["Asakura, Hidesaku","Ogawa, Haruhiko"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302456","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14858","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["D-dimer","Heparin"],"_version_":1664357978518585344,"score":377.33566},{"pmid":32220112,"title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.","text":["Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.","BACKGROUND: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, the application of heparin in COVID-19 has been recommended by some expert consensus due to the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated. METHODS: Coagulation results, medications and outcomes of consecutive patients being classified as severe COVID-19 in Tongji hospital were retrospectively analysed. The 28-day mortality between heparin users and nonusers were compared, also in different risk of coagulopaphy which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result. RESULTS: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin, LMWH) for 7 days or longer. The D-dimer, prothrombin time and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference on 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P=0.910). But the 28-day mortality of heparin users were lower than nonusers In patients with SIC score >/=4 (40.0% vs 64.2%, P=0.029), or D-dimer > 6 fold of upper limit of normal (32.8% vs 52.4%, P=0.017). CONCLUSIONS: Anticoagulant therapy mainly with LMWH appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.","J Thromb Haemost","Tang, Ning","Bai, Huan","Chen, Xing","Gong, Jiale","Li, Dengju","Sun, Ziyong","32220112"],"abstract":["BACKGROUND: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, the application of heparin in COVID-19 has been recommended by some expert consensus due to the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated. METHODS: Coagulation results, medications and outcomes of consecutive patients being classified as severe COVID-19 in Tongji hospital were retrospectively analysed. The 28-day mortality between heparin users and nonusers were compared, also in different risk of coagulopaphy which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result. RESULTS: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin, LMWH) for 7 days or longer. The D-dimer, prothrombin time and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference on 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P=0.910). But the 28-day mortality of heparin users were lower than nonusers In patients with SIC score >/=4 (40.0% vs 64.2%, P=0.029), or D-dimer > 6 fold of upper limit of normal (32.8% vs 52.4%, P=0.017). CONCLUSIONS: Anticoagulant therapy mainly with LMWH appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer."],"journal":"J Thromb Haemost","authors":["Tang, Ning","Bai, Huan","Chen, Xing","Gong, Jiale","Li, Dengju","Sun, Ziyong"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220112","week":"202013|Mar 23 - Mar 29","doi":"10.1111/jth.14817","keywords":["D-dimer","coagulopathy","coronavirus disease 2019","low molecular weight heparin","sepsis"],"source":"PubMed","locations":["Tongji","heparin"],"topics":["Treatment"],"weight":1,"e_drugs":["Heparin, Low-Molecular-Weight","Heparin"],"_version_":1663352135096467456,"score":353.27902},{"pmid":32304156,"title":"Inaccurate conclusions by Tang and colleagues.","text":["Inaccurate conclusions by Tang and colleagues.","I read with interest the study by Tang and colleagues, published March 27, 2020, entitled \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease patients with coagulopathy.\" Unfortunately, this retrospective study came to conclusions that are inaccurate with the information provided. The authors use of the word \"therapy\" implies that patients were given therapeutic doses of anticoagulants, however, doses appear to be most consistent with prophylaxis dosing. The authors report that 94 patients received enoxaparin at 40-60mg/day. They did not specify the route of administration, subcutaneous (SC) or intravenous (IV), nor did they specify the percentage of patients that received which dose. The 40mg per day dose of enoxaparin given SC is the prophylactic dose. The 60mg per day IV dose would be therapeutic for patients weighing 40kg, not a typical weight for an adult patient.","J Thromb Haemost","Greenstein, Yonatan Y","32304156"],"abstract":["I read with interest the study by Tang and colleagues, published March 27, 2020, entitled \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease patients with coagulopathy.\" Unfortunately, this retrospective study came to conclusions that are inaccurate with the information provided. The authors use of the word \"therapy\" implies that patients were given therapeutic doses of anticoagulants, however, doses appear to be most consistent with prophylaxis dosing. The authors report that 94 patients received enoxaparin at 40-60mg/day. They did not specify the route of administration, subcutaneous (SC) or intravenous (IV), nor did they specify the percentage of patients that received which dose. The 40mg per day dose of enoxaparin given SC is the prophylactic dose. The 60mg per day IV dose would be therapeutic for patients weighing 40kg, not a typical weight for an adult patient."],"journal":"J Thromb Haemost","authors":["Greenstein, Yonatan Y"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304156","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14857","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Enoxaparin"],"_version_":1664431720544337920,"score":345.89435},{"pmid":32302462,"title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.","text":["ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.","We read with interest the International Society on Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy in COVID-19 (1). We applaud this group's efforts in releasing a timely article on the pandemic impacting all regions of the globe. While we agree that this interim guidance addresses important considerations for monitoring the disease process, we believe that the proposed treatment strategy of prophylactic low molecular weight heparin (LMWH) to treat severe COVID-19 coagulopathy is an unconvincing strategy. Patients that are critically ill with COVID-19 have hallmark signs of disseminated intravascular coagulation (DIC)(2), and as noted in the ISTH interim guidance and our own clinical practice, thrombosis is the overwhelming phenotype with rare bleeding complications. We address this concern with the existing data on the severe hypercoagulable state of COVID-19 victims and advocate for consideration of systemic anticoagulation with unfractionated heparin to prevent life threatening micro- and macrovascular thrombosis to mitigate their associated consequences, up to and including progression of respiratory and organ failure.","J Thromb Haemost","Barrett, Christopher D","Moore, Hunter B","Yaffe, Michael B","Moore, Ernest E","32302462"],"abstract":["We read with interest the International Society on Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy in COVID-19 (1). We applaud this group's efforts in releasing a timely article on the pandemic impacting all regions of the globe. While we agree that this interim guidance addresses important considerations for monitoring the disease process, we believe that the proposed treatment strategy of prophylactic low molecular weight heparin (LMWH) to treat severe COVID-19 coagulopathy is an unconvincing strategy. Patients that are critically ill with COVID-19 have hallmark signs of disseminated intravascular coagulation (DIC)(2), and as noted in the ISTH interim guidance and our own clinical practice, thrombosis is the overwhelming phenotype with rare bleeding complications. We address this concern with the existing data on the severe hypercoagulable state of COVID-19 victims and advocate for consideration of systemic anticoagulation with unfractionated heparin to prevent life threatening micro- and macrovascular thrombosis to mitigate their associated consequences, up to and including progression of respiratory and organ failure."],"journal":"J Thromb Haemost","authors":["Barrett, Christopher D","Moore, Hunter B","Yaffe, Michael B","Moore, Ernest E"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302462","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14860","keywords":["acute respiratory distress syndrome (ards)","anticoagulation","covid-19","disseminated intravascular coagulation","international society on thrombosis and haemostasis (isth)"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["ISTH"],"_version_":1664357978658045955,"score":289.48392},{"pmid":32302445,"title":"Reply to \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\".","text":["Reply to \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\".","We have just read with interest the article recently published in your Journal and titled \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\" by Tang N. et al (1). In this article, it is suggested that those patients with COVID-19 that accomplish the Sepsis-Induced Coagulopathy (SIC) criteria, and receive anticoagulant treatment would present a reduction of mortality rates. It is well known that both shock and disseminated intravascular coagulation (DIC) are the two major causes of organ dysfunction in sepsis (2). Furthermore, DIC is a strong predictor of mortality in patients with sepsis, independently of the severity of sepsis (2).","J Thromb Haemost","Coto-Hernandez, Ruben","Fabregas Ruano, Maria Teresa","32302445"],"abstract":["We have just read with interest the article recently published in your Journal and titled \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\" by Tang N. et al (1). In this article, it is suggested that those patients with COVID-19 that accomplish the Sepsis-Induced Coagulopathy (SIC) criteria, and receive anticoagulant treatment would present a reduction of mortality rates. It is well known that both shock and disseminated intravascular coagulation (DIC) are the two major causes of organ dysfunction in sepsis (2). Furthermore, DIC is a strong predictor of mortality in patients with sepsis, independently of the severity of sepsis (2)."],"journal":"J Thromb Haemost","authors":["Coto-Hernandez, Ruben","Fabregas Ruano, Maria Teresa"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302445","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14852","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664357978651754498,"score":278.5026}]}